

PREVALENCE OF BISPHOSPHONATE THERAPY IN WOMEN WITH BREAST CANCER TREATED WITH AROMATASE INHIBITORS IN GERMANY

Authors: Jacob L, Kostev K, Hadji P

PURPOSE

The aim of this study is to analyze the prevalence of bisphosphonate therapy in women with breast cancer (BC) treated with aromatase inhibitors (AI) in Germany.

METHODS

We included women with BC who started AI therapy between January 2005 and December 2014 (index date) and were followed for a maximum of 24 months. The number of women who received at least one prescription of bisphosphonate during AI therapy was calculated.

RESULTS

A total of 6,959 women with BC who received AI therapy between 2005 and 2014 were analyzed. Of these, only 202 (2.9%) received bisphosphonates.

CONCLUSIONS

The prevalence of bisphosphonate use was low in women with BC treated with AI.

Published in: *Int J Clin Pharmacol Ther.* 2017 May;55(5):394-396. doi: 10.5414/CP202903



If you would like to read any of the studies in its entirety, please, contact us to obtain the full version of a publication. Also, our research director is at your disposal if you have any further questions.

Thank you for your interest!